SCHEMBL3770097

SCHEMBL3770097

O=C(O)c1cnc(NC2CCNCC2)nc1C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 2/20 0.46
▸ CDK1 P06493 1/20 0.46
▸ CDK4 P11802 1/20 0.46
▸ CCND1 P24385 1/20 0.46
▸ CNR2 P34972 2/20 0.45
▸ PDE5A O76074 1/20 0.43
▸ PDE9A O76083 1/20 0.43
▸ HRH4 Q9H3N8 1/20 0.42
▸ HRH3 Q9Y5N1 1/20 0.42
▸ CSNK2A1 P68400 1/20 0.42
▸ ULK1 O75385 1/20 0.41
▸ MAPK8 P45983 3/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ MAPK1 P28482 2/20 0.40
▸ AXL P30530 1/20 0.39
▸ TYRO3 Q06418 1/20 0.39
▸ MERTK Q12866 1/20 0.39
▸ MAPK9 P45984 2/20 0.39
▸ IRAK4 Q9NWZ3 1/20 0.39
▸ SYK P43405 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12796044 0.85 HDAC3 (0.49) CNR2HDAC1MAPK1MAPK3
SCHEMBL10145847 0.83 CDK1 (0.48) CDK2CDK1CDK4CCND1PDE5A
Hydrochloric Acid SCHEMBL541457 0.82 CDK1 (0.48) CDK2CDK1CDK4CCND1PDE5A
SCHEMBL15397162 0.81 CNR2 (0.46) CNR2ULK1MAPK8HDAC1MAPK1
SCHEMBL1587368 0.81 CNR2 (0.45) CNR2MAPK8HDAC1MAPK9
SCHEMBL1587367 0.81 CNR2 (0.45) CNR2MAPK8HDAC1MAPK9
SCHEMBL1587867 0.81 CNR2 (0.45) CNR2MAPK8HDAC1MAPK9
SCHEMBL13015051 0.81 CNR2 (0.53) CNR2
SCHEMBL13015082 0.78 EPHX1 (0.54) CDK2CDK1CDK4CCND1CNR2
Trifluoroacetic Acid SCHEMBL30915024 0.75 HRH4 (0.49) CDK2CDK1CDK4CCND1HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7855194-B2 Pyrimidine, quinazoline, pteridine and triazine derivatives HOFFMANN-LA ROCHE INC. (US) 2010-12-21 — — US disclosed
EP-2001867-B1 PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2009-07-01 — — EP disclosed
CN-101405284-A Pyrimidine, quinazoline, pteridine and derivatives HOFFMANN LA ROCHE (CH) 2009-04-08 — — CN disclosed
EP-2001867-A2 PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-12-17 — — EP disclosed
WO-2007110340-A2 PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-10-04 — — WO disclosed
US-20070225271-A1 Pyrimidine, quinazoline, pteridine and triazine derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-09-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225271-A1 Pyrimidine, quinazoline, pteridine and triazine derivatives SSTR5, SSTR3, SSTR1 CDK2 945/4885CDK1 956/4885CDK4 1270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback